BioJapan 2026: Asia’s Premier Partnering Event for Life Sciences Innovation
BioJapan 2026 is one of Asia’s largest and most established biotechnology partnering events, bringing together pharmaceutical companies, biotech innovators, researchers, investors, and healthcare organisations from around the world. Taking place in Yokohama, Japan, the event combines exhibitions, expert-led seminars, and a dedicated partnering platform designed to facilitate strategic collaborations, licensing discussions, and business development opportunities. Celebrating its 40th anniversary in 2026, BioJapan continues to be a key meeting point for organisations looking to drive innovation across biotechnology, drug discovery, regenerative medicine, and digital health.
OTS 2026: Advancing the Future of Oligonucleotide Therapeutics
The Oligonucleotide Therapeutics Society (OTS) Annual Meeting 2026 brings together leading researchers, clinicians, biotech innovators, and pharmaceutical companies to explore the latest advances in oligonucleotide-based medicines. Taking place in Denver, Colorado, the conference serves as a premier forum for discussing breakthroughs in RNA therapeutics, gene silencing technologies, delivery systems, and nucleic acid drug development. With a strong emphasis on scientific innovation and translational research, OTS provides an invaluable opportunity for collaboration, networking, and knowledge sharing across the rapidly evolving oligonucleotide therapeutics landscape.
Driving Progress with Innovation in ADC Chemistry, Enhancing Patient Stratification in Clinical Trials, and Maximizing Manufacturing Efficiency to Advance ADCs Toward Standard-of-Care Oncology Therapies
Solidifying ADCs as Standard of Care Therapies by De-Risking Differentiated Payload MoAs Beyond Topo1, Elevating ADCs to Deliver Wider Impact in the Clinical Landscape & Adapting Manufacturing Efficiency for Novel & Cost-Effective ADCs
BIO-Europe 2026: Connecting Biopharma Leaders to Accelerate Innovation and Partnership
BIO-Europe 2026 is Europe’s premier biopharma partnering event, bringing together biotechnology companies, pharmaceutical leaders, investors, and business development professionals from across the global life sciences ecosystem. Taking place in Cologne, Germany, from 9-11 November 2026, the conference provides a dedicated platform for strategic networking, one-to-one partnering meetings, and industry insights. With a strong focus on licensing, investment, collaboration, and business growth, BIO-Europe is widely regarded as one of the most important events for organisations looking to forge new partnerships and advance innovation across the biotechnology sector.
PEGS Europe 2026: Advancing the Future of Protein and Antibody Engineering
PEGS Europe 2026 is one of Europe’s leading conferences for biologics, bringing together more than 1,500 scientists, drug developers, and industry leaders to explore the latest advances in protein and antibody engineering. Taking place in Lisbon, the event covers key areas including multispecific antibodies, AI-driven protein design, next-generation therapeutics, immunoengineering, and biologics development. With a strong focus on innovation and collaboration, PEGS Europe provides a valuable platform for networking, scientific exchange, and discovering emerging technologies shaping the future of drug development.
Evaluating Novel Target Trial Data, Isotope Selection, Dosimetry Assessment, & Share Regulatory Insights to Drive & Achieve RLT Potential as First-Line & Combination Therapies in Modern Oncology.
Targeted radiopharmaceuticals have entered a new era. Clinical success is accelerating investment, pipelines are rapidly expanding beyond lutetium into next-generation alpha emitters and novel targets, and developers are racing to bring transformative radioligand therapies to patients. As the field matures, the industry’s greatest challenges involve clinical translation, isotope availability, manufacturing scale-up and regulatory alignment.
The 8th Targeted Radiopharmaceuticals Summit Europe unites the scientific, clinical, manufacturing, regulatory and commercial leaders driving this transformation to build the blueprint for Europe’s next generation of targeted radiopharmaceuticals.
Uniting TCE Leaders to Optimise Target Selection & Innovate Cell Engager Design to Accelerate Transformative Immunotherapies from Research Towards Clinical Approval.
Returning to London in December 2026, the 2nd T-Cell Engager Therapeutics Summit Europe will bring together industry pioneers and leading experts to showcase the latest advances in target selection technologies, innovative engager designs and strategies for overcoming safety challenges. Across 3 jam-packed days, attendees will gain data-driven insights into accelerating the development of T-cell engager therapeutics across both oncology and autoimmune disease landscapes.